Pulmonary Medicine - Clinical Practice - Prova Education

Episodes 1-16 of 21

- Brendan J. Canning, PhD
  Peer
- Peter Dicpinigaitis, MD
  Peer
3
CME/CE
Opening a New Chapter on the Diagnosis and Management of Unexplained Chronic Cough
Opening a New Chapter on the Diagnosis and Management of Unexplained Chronic Cough
0.25 credits
Opening a New Chapter on the Diagnosis and Management of Unexplained Chronic ...
0.25 credits
- Peter Dicpinigaitis, MD
  Peer
- Brendan J. Canning, PhD
  Peer
5
CME/CE
Unexplained Chronic Cough—Not Just a Disease Symptom, but a Condition unto Itself
Unexplained Chronic Cough—Not Just a Disease Symptom, but a Condition unto Itself
0.25 credits
Unexplained Chronic Cough—Not Just a Disease Symptom, but a Condition unto It...
0.25 credits
- William Mencia, MD, FACEHP, CHCP
  Peer
- Gregory S. Sawicki, MD, MPH
  Peer
3
CME/CE
Cystic Fibrosis: Overcoming Barriers to Nutrition Adherence
Cystic Fibrosis: Overcoming Barriers to Nutrition Adherence
0.25 credits
Cystic Fibrosis: Overcoming Barriers to Nutrition Adherence
0.25 credits
- Angel O. Coz Yataco, MD, FCCP
  Peer
- Julio A. Ramírez, MD, FACP
  Peer
- Charles P. Vega, MD
  Peer
1
CME/CE
Ciencia Emergente en Pacientes de Alto Riesgo: Selección Apropiada de Terapia Antiviral Contra la Influenza
Ciencia Emergente en Pacientes de Alto Riesgo: Selección Apropiada de Terapia Antiviral Contra la Influenza
0.25 credits
Ciencia Emergente en Pacientes de Alto Riesgo: Selección Apropiada de Terapia...
0.25 credits
- Mark A. Socinski, MD
  Peer
- Alexander Drilon, MD
  Peer
10
CME/CE
Keeping Pace: Advances in RET Fusion-Positive NSCLC
Keeping Pace: Advances in RET Fusion-Positive NSCLC
0.25 credits
Keeping Pace: Advances in RET Fusion-Positive NSCLC
0.25 credits
- Mark A. Socinski, MD
  Peer
- Helena Yu, MD
  Peer
8
CME/CE
Keeping Pace: Advances in First-Line Therapy for EGFR-mutated NSCLC
Keeping Pace: Advances in First-Line Therapy for EGFR-mutated NSCLC
0.25 credits
Keeping Pace: Advances in First-Line Therapy for EGFR-mutated NSCLC
0.25 credits
- Julio A. Ramírez, MD, FACP
  Peer
- Charles P. Vega, MD
  Peer
4
CME/CE
Selección Apropiada de Terapia Antiviral Contra la Influenza
Selección Apropiada de Terapia Antiviral Contra la Influenza
0.25 credits
Selección Apropiada de Terapia Antiviral Contra la Influenza
0.25 credits
- Charles P. Vega, MD
  Peer
- Angel O. Coz Yataco, MD, FCCP
  Peer
7
CME/CE
La Influenza: Ciencia Emergente en Pacientes de Alto Riesgo en la Población
La Influenza: Ciencia Emergente en Pacientes de Alto Riesgo en la Población
0.25 credits
La Influenza: Ciencia Emergente en Pacientes de Alto Riesgo en la Población
0.25 credits
- Mark A. Socinski, MD
  Peer
- Gilberto de Lima Lopes Junior, MD, MBA, FAMS
  Peer
5
CME/CE
Keeping Pace: The Use of Immunotherapy in Mutation-Positive Non-Small Cell Lung Cancer
Keeping Pace: The Use of Immunotherapy in Mutation-Positive Non-Small Cell Lung Cancer
0.25 credits
Keeping Pace: The Use of Immunotherapy in Mutation-Positive Non-Small Cell Lu...
0.25 credits
- Mark A. Socinski, MD
  Peer
- Edward B. Garon, MD, MS
  Peer
4
CME/CE
Keeping Pace: The Role of Immunotherapy After Disease Progression
Keeping Pace: The Role of Immunotherapy After Disease Progression
0.25 credits
Keeping Pace: The Role of Immunotherapy After Disease Progression
0.25 credits
- Mark A. Socinski, MD
  Peer
- Suresh S. Ramalingam, MD
  Peer
7
CME/CE
Keeping Pace: The Role of Immunotherapy in the Frontline Setting
Keeping Pace: The Role of Immunotherapy in the Frontline Setting
0.25 credits
Keeping Pace: The Role of Immunotherapy in the Frontline Setting
0.25 credits
- Suneet Mittal, MD FACC FHRS
  Peer
- Aysha Arshad MD, FACC, FHRS, FAHA
  Peer
29
CME/CE
Telemedicine During COVID-19 Outbreak
Telemedicine During COVID-19 Outbreak
0.25 credits
Telemedicine During COVID-19 Outbreak
0.25 credits
- Brian P. McDonough, MD, FAAFP
  Peer
5
Primary Care Today
The Real Cost of Smoking: Medical, Financial, and Societal Considerations
The Real Cost of Smoking: Medical, Financial, and Societal Considerations
The Real Cost of Smoking: Medical, Financial, and Societal Considerations
2
FDA Drug Information Updates
FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk
FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk
FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Ser...
- Robert H. Debbs, DO
  Peer
- Ari Brooks, MD
  Peer
- Paris D. Butler, MD, MPH
  Peer
- Patrick J. Connolly, MD
  Peer
- Taine Pechet, MD
  Peer
- Brian Englander, MD
  Peer
12
Medical Breakthroughs from Penn Medicine
Q&A with Penn Medicine Experts: Hot Topics in Primary Care
Q&A with Penn Medicine Experts: Hot Topics in Primary Care
Q&A with Penn Medicine Experts: Hot Topics in Primary Care
- Matt Birnholz, MD
  Peer
- Taine Pechet, MD
  Peer
14
Medical Breakthroughs from Penn Medicine
A Thoracic Surgeon's Viewpoint on Screening, Diagnosis and Treatment of a Lung Cancer Patient
A Thoracic Surgeon's Viewpoint on Screening, Diagnosis and Treatment of a Lung Cancer Patient
A Thoracic Surgeon's Viewpoint on Screening, Diagnosis and Treatment of a Lu...

Prev
1
2
Next

1/2